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Abstract
Recent studies have suggested that ribosomal protein S12 modulates 16S rRNA function and susceptibility to 2-
deoxystreptamine aminoglycosides. To study whether the non-restrictive K42R mutation in RpsL affects 2-deoxystreptamine
susceptibility in Mycobacterium smegmatis, we studied the drug susceptibility pattern of various mutants with genetic
alterations in the 16S rRNA decoding A-site in the context of wild-type and mutant protein S12. RpsL K42R substitution was
found not to affect the drug resistance pattern associated with mutational alterations in 16S rRNA H44.
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Introduction
Ribosomal protein S12 is a critical component of the A-site of
the 30S ribosomal subunit and is involved in both tRNA selection
and resistance to streptomycin [1,2]. Mutations in rpsL coding for
ribosomal protein S12 are known to affect ribosomal accuracy to
various extents, resulting in what is characterized as error-
restrictive or non-restrictive S12 alterations [3]. Streptomycin
inhibits protein synthesis and makes ribosomes error prone by
affecting initial tRNA selection and proofreading [4]. Mutations in
S12 confer streptomycin resistance by preventing streptomycin
binding and/or conferring ribosomal hyperaccuracy; a strongly
hyperaccurate phenotype may even manifest as streptomycin-
dependence [2]. Various substitutions at positions 42 and 87 are
associated with streptomycin resistance. In particular, mutations
Lys42 R Arg, Ala or Thr promote high levels of streptomycin
resistance; among those Lys42Arg has a non-restrictive phenotype
[3], whereas Lys42Ala and Lys42Thr are strongly error-restrictive
[3,5,6]. S12 substitutions Lys87 R Gln or Gly confer different
degrees of streptomycin resistance [7,8]. The homologous
mammalian ribosomal proteins carry Gln-87 (human mitochon-
drial ribosomes) or Gly-87 (human cytoplasmic ribosomes) in part
accounting specificity of drugs for prokaryotic ribosome [7].
More recently it has been suggested that ribosomal protein S12
modulates 16S rRNA function and susceptibility to 2-deoxystrep-
tamine aminoglycosides [5,6]. 2-deoxystreptamine aminoglyco-
sides are composed of a common core, termed neamine, in which
position 4 of a 2-deoxystreptamine ring (ring II) is attached to a
glycopyranosyl ring (ring I). Additional sugars are attached to
position 5 or 6 of the 2-deoxystreptamine moiety to give rise to
4,5- or 4,6- aminoglycosides (see Supplementary Fig. S1). In 4,5-
aminoglycosides, the core is further substituted by one (ribosta-
mycin), two (neomycin, paromomycin) or three (lividomycin)
additional sugars attached to position 5 of ring II, whereas in 4,6-
aminoglycosides (gentamicin, tobramycin, kanamycin, etc.) the
core is further substituted by one additional sugar attached to
position 6 of ring II. The drug binding pocket for these compounds
consists of an internal loop of 16S rRNA helix 44 – the decoding
A-site of the ribosome [9]. We have previously performed
extensive genetic studies of 16S rRNA helix 44 in Mycobacterium
smegmatis to address the role of individual rRNA residues in drug
binding (reviewed in [10]). These studies have been conducted
mainly in the genetic background of a non-restrictive K42R
mutation in ribosomal protein S12 [10–16]. The K42R mutation
confers high-level resistance to streptomycin and was used as
counter-selectable marker in strain construction [15]. The recent
reports on the interplay of S12 on 16S rRNA function and
susceptibility to 2-deoxystreptamine aminoglycosides prompted us
to study in detail the role, if any, between RpsL K42R and
mutational alterations in 16S rRNA helix 44 conferring resistance
to 2-deoxystreptamines. We find that the non-restrictive RpsL
K42R mutation does not affect the 2-deoxystreptamine suscepti-
bility of various rRNA mutations in M. smegmatis H44.
Results and Discussion
Generation of M. smegmatis strains with mutations in S12
and 16S rRNA
M. smegmatis was the first eubacterial model organism that was
made single rRNA allelic by means of deletion mutagenesis and
that allowed for genetic studies of its ribosomal RNA [16]. As a
gram-positive mesophilic bacterium, M. smegmatis is susceptible to a
number of ribosomal antibiotics and sets itself apart from other
model organisms by being a close representative of clinically
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to 2-deoxystreptamine aminoglycoside antibiotics relied on M.
smegmatis strains with a K42R mutation in ribosomal protein S12
[10–16]. To substantiate the results and conclusions drawn from
these early studies, we constructed a comprehensive set of M.
smegmatis rRNA mutants in the context of both a wild-type and a
mutant S12 (Table S1). The set of 16S rRNA mutants includes
alterations of positions 1408 (A1408G), 1491 (G1491C; G1491U;
G1491A) and 1409 (C1409U; C1409G).
Aminoglycoside susceptibility of M. smegmatis mutants
Aminoglycoside susceptibility of the mutant strains was
determined by minimal inhibitory concentration (MIC) assays.
Representatives for each of the two disubstituted 2-deoxystrepta-
mine subclasses were included: the 4,5-disubstituted 2-deoxystrep-
tamines paromomycin and neomycin and the 4,6-disubstituted 2-
deoxystreptamines gentamicin, tobramycin and kanamycin. The
results are presented in Table 1.
Among all A-site mutations that confer aminoglycoside
resistance, the A1408G mutation is the most significant. In M.
smegmatis, the A1408G mutation confers moderate resistance to
paromomycin (69 OH) but high level resistance to 2-deoxystrepta-
mine aminoglycosides with an amino group at the 69 position of
ring I. A key element in drug binding is the pseudo base-pair
interaction between the ring of the aminoglycosides I and A 1408
[13,17,18]. In case of an adenine, the oxygen of ring I accepts a
hydrogen bond from the N6 of A1408, and the amino or hydroxyl
group at position 69 donates a hydrogen bond to the N1 of
adenine, accounting for two direct hydrogen bonds between ring I
and A1408 (Fig. 1). In case of a 1408 guanine, the 69 amino group
of ring I can no longer form an H bond with the Watson-Crick
edge of residue 1408. Additionally, the positive charge of the 69
amino group creates repulsion against the N1 and N2 amino
groups of guanine. As a consequence, the A to G mutation
prevents aminoglycoside binding by precluding the proper
insertion of ring I into the binding site. In contrast, a 69- hydroxyl
group, as in paromomycin could still become an acceptor of an H
bond from N1 or N2 of the guanine, although the resulting pseudo
base pair does not appear to promote optimal insertion of ring I, as
indicated by decreased ribosomal drug susceptibility.
The Watson–Crick base pair C1409–G1491 forms the base of
the drug binding pocket. In the crystal structures [17,18], G1491
provides a stacking interaction with ring I of the aminoglycosides,
thereby stabilizing the pseudo base-pair interaction of ring I with
A1408 (Fig. 1). Among all mutations investigated affecting base-
pair interaction C1409-G1491, the transversion mutations
G1491C and G1491U (resulting in pyrimidine-pyrimidine oppo-
sitions) confer the highest level of resistance, in particular to
paromomycin. Presumably, a pyrimidine-pyrimidine opposition
provides a conformation that sterically hinders the correct
positioning of ring I. A pyrimidine-purine opposition is retained
following transition of G1491 to A resulting in C1409–1491A.
This mutational alteration apparently interferes less with drug
binding, as indicated by the drug susceptibility pattern of the
mutants. The C1409U mutant shows little resistance to amino-
glycosides. Nucleotide C1409 is not involved directly in drug
binding, but is responsible for the correct orientation of nucleotide
1491, as 1409 and 1491 form a Watson–Crick base pair. The
mutant wobble-base pair interaction 1409U–G1491 is likely to
show conformational characteristics resembling those of the wild-
type C–G. Mutation C1409G leads to a purine–purine opposition
1409G–G1491 in which the exact nature of interaction is difficult
to predict. Surprisingly, the resistance levels conferred by this
mutation are low to moderate. In general, sequence alterations in
C1409-G1491 while mostly affecting the 69 OH paromomycin do
not discriminate between 4,5- and 4,6-aminoglycosides [10]. This
is in agreement with the structural observation that ring I binds in
the same orientation irrespective of the substituents at the 2-
deoxystreptamine ring [18].
Strains with mutations in 16S rRNA residues 1408, 1409 and
1491 show a mutation-specific drug susceptibility pattern that is
independent of the amino acid residue 42 in ribosomal protein S12
(wt vs K42R, see Table 1) and that corresponded to previously
published data [12]. These results demonstrate that the K42R
mutation in ribosomal protein S12 does not affect the susceptibility
of M. smegmatis H44 mutants to 2-deoxystreptamines. Notably, this
Table 1. Drug susceptibility of M. smegmatis 16S rRNA mutants: wild-type S12 versus K42R.
16S rRNA residues S12 MIC (mg/mL) Reference
1408 1409–1491 Pm Nm Gm Tb Km
AC ;G wt 1 0.5 1 1 0.5–1 this study
AC ;G K42R 1 1 1 1 0.5–1 [13]
GC ;Gw t 6 4 .1024 .1024 .1024 .1024 this study
GC ;G K42R 64 $1024 .1024 .1024 .1024 [12]
AC ? C wt 512 16 16–32 16 16–32 this study
AC ? C K42R 512 16–32 16–32 16–32 16–32 [12]
AC ? U wt 512–1024 8–16 32–64 64 64–128 this study
AC ? U K42R 512 8–16 32 32–64 128 [12]
AC ? A wt 32–64 2 2 2 1–2 this study
AC ? A K 4 2 R 3 2 4242 [ 1 2 ]
AU ? G wt 4–8 0.5–1 8 8–16 8–16 this study
AU ? G K42R 4–8 1 8–16 8–16 16 [12]
AG ? G wt 32–64 4–8 1–2 8–16 32–64 this study
AG ? G K42R 16–32 4 2–4 8–16 16–32 [12]
Pm, paromomycin; Nm, neomycin; Gm, gentamicin; Tb, tobramycin; Km, kanamycin A.
doi:10.1371/journal.pone.0011960.t001
Mutation K42R in R-Protein S12
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where K42R (the rpsL226 allele) reportedly modulated the level of
paromomycin resistance of a G1491U mutant [19].
To study whether the different findings reported for E. coli are
due to phylogenetic differences in the decoding-site rRNA, we
constructed M. smegmatis with a proteobacteria-like helix 44
(Fig. 2). M. smegmatis and E. coli differ in 16S rRNA residues
1410–1490 and 1411–1489: 1410–1490 G-C (M. smegmatis) versus
A-U (E. coli), 1411–1489 U-A (M. smegmatis) versus C-G (E. coli).
We found that the various H44 mutations (A1408G, G1491A,
G1491C, G1491U) resulted in identical drug susceptibility
patterns regardless of a mycobacterial and proteobacterial H44
sequence context at residues 1410–1490 and 1411–1489 (data not
shown).
Structural analysis of K42 mutations
Crystal structures of streptomycin bound to the small ribosomal
subunit of T. thermophilus [17] have revealed two direct hydrogen
bonds between streptomycin and the lysine residue 42 of
ribosomal protein S12 (Fig. 3A, 3B). K42 forms an additional
contact to the phosphate backbone of 16S rRNA helix 27 (H27)
via a salt bridge to the phosphate group of residue A913.
Superimposition of the K42R substitution disrupts the hydrogen
bonding to streptomycin (Fig. 3C), accounting for the streptomy-
cin resistance of K42R mutants. However, amino-acid substitution
K42R leaves the salt bridge to H27 intact (Fig. 3C). Thus, the
general structure of the A-site remains intact and rate and fidelity
of translation remains unaffected [17]. This is in agreement with
the observation that K42R is the only known mutation in S12 that
Figure 1. Stacking interaction of ring I with G1491 and pseudo-base pairing of ring I with A1408. The hydrogen bonding contacts
between ring I and A1408 are indicated by black broken lines.
doi:10.1371/journal.pone.0011960.g001
Figure 2. Secondary structure of 16S rRNA helix 44 in the ribosomal decoding site. (A) Decoding site of E. coli wild-type (Proteobacteria).
Four nucleotide positions depicted in green represent residues that are specific for E. coli 16S rRNA. (B) Decoding site of M. smegmatis wild-type
(Mycobacteria). (C) Decoding site of M. smegmatis mutagenised to correspond to the polymorphism observed in E. coli i.e., Eco4.
doi:10.1371/journal.pone.0011960.g002
Mutation K42R in R-Protein S12
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result in a hyper-accurate (i.e. restrictive) phenotype [3].
In contrast to K42R, mutations K42A or K42T disrupt the salt
bridge to H27 (Fig. 3D, 3E). This mostly accounts for the
restrictive phenotype of these mutations [17]. While K42A does
not interfere with the binding of paromomycin directly [5], the
hyperaccurate phenotype of the variant K42A ribosome in part
functionally antagonizes aminoglycoside-induced misreading.
Thus, these ribosomes show paromomycin-induced misreading
only at much higher drug concentrations compared to wild-type
[5].
Conclusions
Our data demonstrate that K42R in ribosomal protein S12 does
not affect resistance to 2-deoxystreptamine aminoglycosides as
conferred by 16S rRNA mutations in H44, and that S12 most
likely plays little role in the species-specific pattern of susceptibility
to 2-deoxystreptamines. This conclusion is supported by the
Figure 3. Three-dimensional crystal structure of T. thermophilus ribosomal decoding A-site with bound paromomycin and
streptomycin. (A) General view of the A-site. Amino-acid residues of S12 (green) are shown labelled according to atoms: carbon – green, nitrogen –
blue, oxygen – red. 16S rRNA helices are indicated as follows: H44 strand I (pink), H44 strand II (magenta), H27 (violet), H18 (orange). Streptomycin
(light blue) and paromomycin (yellow). (B) Close up of wild type K42. Hydrogen bonds to streptomycin (black dotted lines) and salt bridge to A913
(red dotted line) are shown. (C) Close up of mutant K42R. Salt bridge (red dotted line) is shown. (D) Close up of mutant K42A. (E) Close up of mutant
K42T. (Protein Data Bank, 1FJG.pdb).
doi:10.1371/journal.pone.0011960.g003
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rRNA (homologous to E. coli residue A1408/G1491) reversed the
natural resistance of yeast cytoplasmic ribosomes, i.e, increased the
susceptibility to aminoglycosides from completely resistant
(MIC.5000 mg/ml) up to highly susceptible (MIC about 3 mg/
ml). These levels of drug susceptibility are similar to those found in
drug susceptible E. coli (MIC about 2.5–5 mg/ml) [20]. Thus,
irrespective of ribosomal protein S12 (S. cerevisiae or E. coli),
susceptibility to 2-deoxystreptamines is apparently determined by
the nucleotide residues in drug binding pocket of 16S rRNA. This
finding contrasts with the view of a universal interrelation between
S12, base pair 1409–1491 and 2-deoxystreptamine susceptibility.
Instead, it suggests that functional interactions between S12 and
the 2-deoxystreptamine binding site are limited to certain bacterial
genera and/or specific rpsL mutations. Interaction of S12 and 2-
deoxystreptamine aminoglycosides apparently is not at the level of
drug binding, but provoked by interference of two opposite effects
on translation fidelity induced by error-restrictive rpsL mutations
and misreading-inducing aminoglycoside antibiotics. As a result,
this interplay is limited to S12 amino acid substitutions which
confer a hyperaccurate phenotype and thus are functional
antagonists of drug-induced misreading.
Materials and Methods
Strains used in this study
A single rRNA allelic strain M. smegmatis DrrnB (SZ380) was
generated by unmarked deletion mutagenesis of the rrnB operon in
M. smegmatis mc
2155. A suicide vector pH022 containing two DNA
fragments flanking the rrnB operon (generated by PCR), a
selectable marker (Gm
R) and counter-selectable marker sacB (both
outside the rrnB DNA fragments), was transformed into M.
smegmatis mc
2155. A single rRNA allelic derivative was obtained by
a two-step selection procedure: selection of transformants on agar
plates containing gentamicin followed by a counter-selection step
on agar plates with sucrose. Deletion of rrnB was confirmed by
Southern blot analysis and partial sequencing.
Mutagenesis of the H44 decoding-site RNA was performed in
strain M. smegmatis DrrnB (SZ380) and in strain M. smegmatis DrrnB
rpsL K42R (SZ004) [12]. rRNA mutations were generated by
PCR, cloned into vector pMIH-rrnB and introduced into the 16S
rRNA A-site of the single rRNA allelic strain SZ0380 by RecA-
mediated homologous recombination as described [12]. For a list
of strains and plasmids see Tables S1 and S2 in Supplementary
Data.
Minimal inhibitory concentration (MIC) assay
Drug susceptibility was studied by determining Minimal
Inhibitory Concentrations (MIC). MIC tests were performed in
a microtiter plate format as described [12]. In brief, freshly grown
M. smegmatis cultures were resuspended in LB broth supplemented
with 0.05% of Tween 80, diluted to an absorbance at 600 nm of
0.025 and incubated in the presence of 2-fold serial dilutions of 2-
deoxystreptamine aminoglycosides. After incubation at 37uC for
72 h, the MIC was recorded as the lowest concentration of drug
inhibiting visible growth.
Structural modelling
PyMol (DeLano Scientific) was used to render the structure of
the A-site of 30S ribosomal subunit from T. thermophilus (Protein
Data Bank, 1FJG.pdb) [21].
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